The solution is here — in your DNA
Genetic factors can account for up to 95% of drug-response variability and susceptibility.3 In other words, how a drug will—or won't—work for a particular individual. Our RightMed® test brings pharmacogenomics to everyone, identifying how a patient's DNA and current medications may affect their response to drugs. OneOme: making prescriptions personal.
The OneOme RightMed solution is:
Healthcare of the future.
Cost-effective, comprehensive, personalized pharmacogenomic analysis — integrated into patients' everyday clinical care.
OneOme helps healthcare providers choose the optimal drug therapy the first time, thanks to targeted and evidence-based inputs using each patient's DNA and current prescriptions.
Swab. Send. Know.
The physician-ordered OneOme RightMed comprehensive test identifies which prescription drugs are—or aren’t—likely to work based on your genetic makeup and current prescription interactions. OneOme generates a clear, actionable report to help your physicians to personalize your prescriptions.
The latest at OneOme
MINNEAPOLIS (October 26, 2017) – The Concierge Medicine Forum held this week in Atlanta will feature an expert on pharmacogenomics from OneOme, a leading precision medicine company. Ryan Gregg, Ph.D, medical science liaison from OneOme, will present a session on pharmacogenomics on ...
WEBINARS & EVENTS
OneOme is a Palladium Sponsor for the 2017 Concierge Medicine Forum, October 27-28 in Atlanta, GA..
SINGAPORE, MINNEAPOLIS (October 11, 2017) – In Singapore, OneOme and Tucker Medical are working together to help improve preventive care and oncology treatments. OneOme is a leader in pharmacogenomic testing and Tucker Medical is a multi-specialty practice offering...
In this webinar, we will walk through the newly released product updates and enhancements, including the:
● identify the genes that impact the metabolism and activity of opioid and non-opioid analgesics
● discuss how pharmacogenomic variants can affect the safety of pain management medications
● evaluate clinical studies investigating pharmacogenomic testing in treating postoperative pain, cancer-related pain, and pain in pediatrics
MINNEAPOLIS (October 10, 2017) – Today, OneOme announced it has been named a finalist for the 18th Annual Minnesota High Tech Association (MHTA) Tekne Awards in the Healthcare category. The Tekne Awards honor Minnesota companies and individuals who have shown superior technology innovation and lea...
WEBINARS & EVENTS
2017 NEI Congress
OneOme will exhibit at the 2017 NEI Congress, November 8-12 in Colorado Springs, CO. Come visit us at booth 205.
“Before OneOme, only those with deep financial resources or the critically ill could
access the power of pharmacogenomics. Today, patients at Ridgeview can receive
personalized prescription insights that previously were inaccessible to them. Not only
will our patients see better health outcomes – they are also avoiding life-threatening
adverse drug reactions, which are the fourth leading cause of death.”
- Bob Stevens, President and CEO of Ridgeview Medical Center